Effect of Mint and Mefnamic Acid on Menstrual Pain

Evaluation of Mint efficacy on primary dysmenorrhea in comparison with Mefnamic Acid

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201011205206N1

Enrollment

432

Registered

2011-02-06

Start date

2011-02-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary dysmenorrhea. Primary dysmenorrhoea

Interventions

Intervention 1: Intervention group1: Peppermint oil capsule (commercial name:colpermin) TDS for 3 days. Intervention 2: Intervention group 2: Mefenamic acid capsule (commercial name: Ponstan) manufact

Treatment - Drugs

Placebo

Intervention group1: Peppermint oil capsule (commercial name:colpermin) TDS for 3 days

Intervention group 2: Mefenamic acid capsule (commercial name: Ponstan) manufactured by Razak Co. 250 mg TDS for 3 days

Control group: Placebo capsule containing sugar

Eligibility

Sex/Gender

Female

Age

18 Years to 25 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: a) Primary dysmenorrhea; b) Single; c) 18-25 years old. Exclusion criteria: a) Contraindication of mint including obstruction of common bile duct, allergy, cholecystitis, chronic liver disease, and gastroesophageal reflux, b) contraindication of mefenamic acid including: allergy, gastritis, gastric ulcer, chronic renal failure, chronic liver disease, anemia, asthma, diabetes mellitus.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Duration of Dysmenorrhea. Timepoint: After taking. Method of measurement: Standard questionnaire (COX).;Severity of Menstrual pain. Timepoint: After taking. Method of measurement: Standard questionnaire of pain violence(vas).;Amount of menstrual bleeding. Timepoint: End of menstrual periods. Method of measurement: Standard questionnaire of Hylgam menstrual bleeding.;Nausea. Timepoint: End of menstrual periods. Method of measurement: Questionnaire.;Vomiting. Timepoint: End of menstrual periods. Method of measurement: Questionnaire.;Diarrhea. Timepoint: End of menstrual periods. Method of measurement: Questionnaire.	—

Measure

Time frame

Duration of Dysmenorrhea. Timepoint: After taking. Method of measurement: Standard questionnaire (COX).;Severity of Menstrual pain. Timepoint: After taking. Method of measurement: Standard questionnaire of pain violence(vas).;Amount of menstrual bleeding. Timepoint: End of menstrual periods. Method of measurement: Standard questionnaire of Hylgam menstrual bleeding.;Nausea. Timepoint: End of menstrual periods. Method of measurement: Questionnaire.;Vomiting. Timepoint: End of menstrual periods. Method of measurement: Questionnaire.;Diarrhea. Timepoint: End of menstrual periods. Method of measurement: Questionnaire.

—

Secondary

Measure	Time frame
Side effects. Timepoint: After taking. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactJalal Poorolajal

Hamadan University of Medical Sciences

poorolajal@umsha.ac.ir; poorolajal@yahoo.com+98 81 1826 0661

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026